Candel Therapeutics Prices $100 Million Share Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CADL?
Source: NASDAQ.COM
- Share Offering Pricing: Candel Therapeutics has priced 18.35 million common shares at $5.45 each, aiming to raise $100 million, although the stock fell 11.76% to $5.25, indicating a negative market reaction to the offering.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated to critical launch readiness, medical affairs, and commercialization activities for aglatimagene besadenovec (CAN-2409) in early localized prostate cancer, as well as ongoing phase 3 trial costs for non-small cell lung cancer, demonstrating the company's commitment to oncology.
- Significant Clinical Progress: Candel recently completed successful phase 2a trials of aglatimagene in non-small cell lung cancer and pancreatic ductal adenocarcinoma, and is conducting a phase 3 trial in localized prostate cancer, showcasing the potential of its lead product candidate.
- FDA Accelerated Approvals: The FDA has granted Fast Track and Regenerative Medicine Advanced Therapy Designations to aglatimagene for newly diagnosed localized prostate cancer, Fast Track for NSCLC, and both Fast Track and Orphan Drug Designations for PDAC, enhancing its competitive edge and commercialization prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CADL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CADL
Wall Street analysts forecast CADL stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.850
Low
7.00
Averages
18.33
High
25.00
Current: 5.850
Low
7.00
Averages
18.33
High
25.00
About CADL
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Stock Futures Rise as Market Awaits GDP Data Release
- Market Sentiment Rebounds: U.S. stock futures rose after closing lower on Thursday, with all major benchmark indices showing positive trends, indicating investor anticipation for the upcoming fourth-quarter GDP data that could influence future monetary policy.
- Stable Rate Expectations: The CME Group's FedWatch tool indicates a 94% likelihood that the Federal Reserve will keep interest rates unchanged in March, providing some stability to the market despite ongoing inflation pressures.
- Divergent Stock Performances: Copart Inc. (NASDAQ: CPRT) dropped 6.64% following disappointing second-quarter earnings, while Comfort Systems USA Inc. (NYSE: FIX) rose 4.57% after reporting better-than-expected financial results, reflecting varied market reactions to company fundamentals.
- Analyst Optimism: Scott Wren from Wells Fargo upgraded the U.S. GDP growth forecast from 2.4% to 2.9%, and despite increased market volatility, he recommends investors focus on sectors like Financials and Industrials that benefit from economic growth, viewing current dips as opportunities to enter large- and mid-cap stocks.
See More
Candel Therapeutics Prices $100 Million Share Offering
- Share Offering Pricing: Candel Therapeutics has priced 18.35 million common shares at $5.45 each, aiming to raise $100 million, although the stock fell 11.76% to $5.25, indicating a negative market reaction to the offering.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated to critical launch readiness, medical affairs, and commercialization activities for aglatimagene besadenovec (CAN-2409) in early localized prostate cancer, as well as ongoing phase 3 trial costs for non-small cell lung cancer, demonstrating the company's commitment to oncology.
- Significant Clinical Progress: Candel recently completed successful phase 2a trials of aglatimagene in non-small cell lung cancer and pancreatic ductal adenocarcinoma, and is conducting a phase 3 trial in localized prostate cancer, showcasing the potential of its lead product candidate.
- FDA Accelerated Approvals: The FDA has granted Fast Track and Regenerative Medicine Advanced Therapy Designations to aglatimagene for newly diagnosed localized prostate cancer, Fast Track for NSCLC, and both Fast Track and Orphan Drug Designations for PDAC, enhancing its competitive edge and commercialization prospects.
See More
Candel Therapeutics Prices $100M Public Offering
- Offering Size: Candel Therapeutics has announced a public offering of 18,348,624 shares at a price of $5.45 per share, with expected gross proceeds of $100 million, although actual revenue may decrease after underwriting discounts and other expenses.
- Closing Timeline: The offering is expected to close on or about February 23, 2026, subject to customary closing conditions, which may impact the company's liquidity and short-term financial health.
- Market Reaction: Following the announcement of the offering, Candel Therapeutics' stock price has declined, reflecting market concerns regarding the company's future growth potential, which could affect investor confidence.
- Strategic Implications: This offering will provide Candel with funding to support its R&D projects; despite the negative market reaction, successful financing will help the company maintain operations and innovation capabilities in the competitive biopharmaceutical industry.
See More
Candel Therapeutics Prices $100 Million Public Offering
- Offering Size: Candel Therapeutics announced a public offering of 18,348,624 shares at $5.45 per share, aiming to raise $100 million, reflecting strong market confidence in its biological immunotherapies.
- Use of Proceeds: The funds will support the commercialization readiness of aglatimagene besadenovec (CAN-2409) for early localized prostate cancer and ongoing phase 3 trials in non-small cell lung cancer, indicating a strategic focus on cancer treatment.
- Underwriting Team: Citigroup, Cantor, and Stifel are acting as joint bookrunning managers for the offering, with LifeSci Capital as lead manager, showcasing robust market support and trust in Candel.
- Regulatory Compliance: Candel's S-3 registration statement filed with the SEC in August 2025 has been approved, ensuring compliance for the offering and enhancing investor confidence in the company's future growth.
See More
Candel Therapeutics Prices Public Offering at $5.45 per Share
- Offering Size: Candel Therapeutics announced a public offering of 18,348,624 shares at a price of $5.45 per share, with expected gross proceeds of $100 million, aimed at funding critical launch readiness and clinical development activities.
- Use of Proceeds: The funds will support commercialization efforts for aglatimagene besadenovec (CAN-2409) in early localized prostate cancer and ongoing phase 3 trials for non-small cell lung cancer, demonstrating the company's commitment to drug development.
- Underwriting Team: The offering is managed by Citigroup, Cantor, and Stifel as joint bookrunning managers, with LifeSci Capital as the lead manager, indicating strong backing and confidence in the capital markets.
- Regulatory Compliance: Candel has filed a registration statement with the SEC, which has been declared effective, ensuring compliance and transparency for the offering, thereby enhancing investor confidence.
See More
Candel Launches $100 Million Public Offering
- Clear Fund Utilization: Candel Therapeutics has announced a $100 million public offering, with proceeds earmarked for commercialization preparations for early-stage localized prostate cancer, including medical affairs and launch readiness, aiming to pave the way for the potential launch of Aglatimagene Besadenovec (CAN-2409).
- Clinical Trial Support: A portion of the funds will support the ongoing phase 3 trial of CAN-2409 in non-small cell lung cancer, ensuring continued development and regulatory progress in key markets, thereby enhancing the company's competitiveness in oncology.
- Negative Stock Reaction: Despite Candel announcing a $100 million royalty funding agreement with RTW Investments on the same day, shares fell 14% in extended trading, reflecting market concerns over the public offering plan, which may impact investor confidence.
- Market Sentiment Analysis: On Stocktwits, retail sentiment for CADL is deemed 'extremely bullish' amid high message volume, with investors expressing optimism about the company's pipeline potential, although there are concerns regarding the participation of low-quality investors, indicating mixed market perceptions about future performance.
See More
U.S. Stock Futures Rise as Market Awaits GDP Data Release
- Market Sentiment Rebounds: U.S. stock futures rose after closing lower on Thursday, with all major benchmark indices showing positive trends, indicating investor anticipation for the upcoming fourth-quarter GDP data that could influence future monetary policy.
- Stable Rate Expectations: The CME Group's FedWatch tool indicates a 94% likelihood that the Federal Reserve will keep interest rates unchanged in March, providing some stability to the market despite ongoing inflation pressures.
- Divergent Stock Performances: Copart Inc. (NASDAQ: CPRT) dropped 6.64% following disappointing second-quarter earnings, while Comfort Systems USA Inc. (NYSE: FIX) rose 4.57% after reporting better-than-expected financial results, reflecting varied market reactions to company fundamentals.
- Analyst Optimism: Scott Wren from Wells Fargo upgraded the U.S. GDP growth forecast from 2.4% to 2.9%, and despite increased market volatility, he recommends investors focus on sectors like Financials and Industrials that benefit from economic growth, viewing current dips as opportunities to enter large- and mid-cap stocks.
See More
Candel Therapeutics Prices $100 Million Share Offering
- Share Offering Pricing: Candel Therapeutics has priced 18.35 million common shares at $5.45 each, aiming to raise $100 million, although the stock fell 11.76% to $5.25, indicating a negative market reaction to the offering.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated to critical launch readiness, medical affairs, and commercialization activities for aglatimagene besadenovec (CAN-2409) in early localized prostate cancer, as well as ongoing phase 3 trial costs for non-small cell lung cancer, demonstrating the company's commitment to oncology.
- Significant Clinical Progress: Candel recently completed successful phase 2a trials of aglatimagene in non-small cell lung cancer and pancreatic ductal adenocarcinoma, and is conducting a phase 3 trial in localized prostate cancer, showcasing the potential of its lead product candidate.
- FDA Accelerated Approvals: The FDA has granted Fast Track and Regenerative Medicine Advanced Therapy Designations to aglatimagene for newly diagnosed localized prostate cancer, Fast Track for NSCLC, and both Fast Track and Orphan Drug Designations for PDAC, enhancing its competitive edge and commercialization prospects.
See More
Candel Therapeutics Prices $100M Public Offering
- Offering Size: Candel Therapeutics has announced a public offering of 18,348,624 shares at a price of $5.45 per share, with expected gross proceeds of $100 million, although actual revenue may decrease after underwriting discounts and other expenses.
- Closing Timeline: The offering is expected to close on or about February 23, 2026, subject to customary closing conditions, which may impact the company's liquidity and short-term financial health.
- Market Reaction: Following the announcement of the offering, Candel Therapeutics' stock price has declined, reflecting market concerns regarding the company's future growth potential, which could affect investor confidence.
- Strategic Implications: This offering will provide Candel with funding to support its R&D projects; despite the negative market reaction, successful financing will help the company maintain operations and innovation capabilities in the competitive biopharmaceutical industry.
See More
Candel Therapeutics Prices $100 Million Public Offering
- Offering Size: Candel Therapeutics announced a public offering of 18,348,624 shares at $5.45 per share, aiming to raise $100 million, reflecting strong market confidence in its biological immunotherapies.
- Use of Proceeds: The funds will support the commercialization readiness of aglatimagene besadenovec (CAN-2409) for early localized prostate cancer and ongoing phase 3 trials in non-small cell lung cancer, indicating a strategic focus on cancer treatment.
- Underwriting Team: Citigroup, Cantor, and Stifel are acting as joint bookrunning managers for the offering, with LifeSci Capital as lead manager, showcasing robust market support and trust in Candel.
- Regulatory Compliance: Candel's S-3 registration statement filed with the SEC in August 2025 has been approved, ensuring compliance for the offering and enhancing investor confidence in the company's future growth.
See More
Candel Therapeutics Prices Public Offering at $5.45 per Share
- Offering Size: Candel Therapeutics announced a public offering of 18,348,624 shares at a price of $5.45 per share, with expected gross proceeds of $100 million, aimed at funding critical launch readiness and clinical development activities.
- Use of Proceeds: The funds will support commercialization efforts for aglatimagene besadenovec (CAN-2409) in early localized prostate cancer and ongoing phase 3 trials for non-small cell lung cancer, demonstrating the company's commitment to drug development.
- Underwriting Team: The offering is managed by Citigroup, Cantor, and Stifel as joint bookrunning managers, with LifeSci Capital as the lead manager, indicating strong backing and confidence in the capital markets.
- Regulatory Compliance: Candel has filed a registration statement with the SEC, which has been declared effective, ensuring compliance and transparency for the offering, thereby enhancing investor confidence.
See More
Candel Launches $100 Million Public Offering
- Clear Fund Utilization: Candel Therapeutics has announced a $100 million public offering, with proceeds earmarked for commercialization preparations for early-stage localized prostate cancer, including medical affairs and launch readiness, aiming to pave the way for the potential launch of Aglatimagene Besadenovec (CAN-2409).
- Clinical Trial Support: A portion of the funds will support the ongoing phase 3 trial of CAN-2409 in non-small cell lung cancer, ensuring continued development and regulatory progress in key markets, thereby enhancing the company's competitiveness in oncology.
- Negative Stock Reaction: Despite Candel announcing a $100 million royalty funding agreement with RTW Investments on the same day, shares fell 14% in extended trading, reflecting market concerns over the public offering plan, which may impact investor confidence.
- Market Sentiment Analysis: On Stocktwits, retail sentiment for CADL is deemed 'extremely bullish' amid high message volume, with investors expressing optimism about the company's pipeline potential, although there are concerns regarding the participation of low-quality investors, indicating mixed market perceptions about future performance.
See More
